Teva Pharmaceuticals has successfully completed its $6.2bn acquisition of Cephalon following approval from European regulators.
Following the European Commission approval, Teva will divest marketing rights in France for a generic version of Cephalon narcolepsy medication Provigil.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The move comes after US authorities requested that Teva allow Par Pharmaceuticals to market a separate generic copy of Provigil for a year.
The acquisition has been designed to allow Teva to offset revenue losses associated with the patent expiry of multiple sclerosis drug Copaxone, the company’s biggest selling product.
